Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Budesonide-MMX in mild to moderate active ulcerative colitis
2006-004776-12Phase 3Completed
- Sponsor
- Cosmo Pharmaceuticals
- Start
- Apr 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of budesonide MMX in autoimmune colitis (4 arms), sponsored by Cosmo Pharmaceuticals. Primary endpoint: Clinical remission at 8 weeks. Started Apr 2008; status: completed.
02
Drugs
budesonide MMX
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2006-004776-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004776-12.